Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors

NCT07299747 is registered in ClinicalTrials.gov with VelaVigo Bio Inc as lead sponsor.

NCT NCT07299747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07299747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors
Lead sponsor
VelaVigo Bio Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
December 1, 2028
Enrollment
255 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

participants with advanced solid tumor malignancies